FDA Approves RiVive™ (naloxone hydrochloride 3 mg) Over-the-Counter Nasal Spray for the Emergency Treatment of Opioid Overdose
Harm Reduction Therapeutics (HRT), Inc., has announced that the FDA has approved OTC RiVive™ (naloxone HCl nasal spray 3 mg) for the emergency treatment of opioid overdose. It is not a controlled substance, according to the US Drug Enforcement Administration (DEA).
This critical milestone will help prevent opioid overdose deaths by making free or low-cost, over the counter (OTC) naloxone nasal spray available to everyone in the United States.
RiVive nasal spray works by rapidly reversing the opioid’s effects as it is an opioid antagonist. RiVive competes for the opiate receptors in the brain and other areas of the body to help reverse the dangerous effects of the opioid so that the patient’s breathing improves, they become more awake, and their blood pressure normalizes.
It is expected that RiVive nasal spray will be available in early 2024
